Leukemic signaling and DNA integrity pathways

Leukemic signaling and DNA integrity pathways refer to a broad set of molecular mechanisms that drive the development, progression, and survival of leukemic cells. Leukemic signaling involves the aberrant activation of pathways such as JAK/STAT, PI3K/AKT/mTOR, and MAPK/ERK, often triggered by mutations in kinases like FLT3 or the formation of fusion proteins like BCR-ABL1 (Source: NIH - National Cancer Institute). DNA integrity pathways, specifically the DNA Damage Response (DDR), are critical for maintaining the genome; however, leukemic cells often harbor defects in these pathways (e.g., TP53 or ATM mutations) that contribute to genomic instability while simultaneously relying on remaining repair mechanisms to survive replication stress (Source: PubMed - PMID: 30237458). Therapeutic intervention typically involves small-molecule inhibitors that target these signaling nodes or exploit DDR vulnerabilities through synthetic lethality, such as using PARP inhibitors in the context of homologous recombination deficiency (Source: Nature Reviews Drug Discovery). Because this term describes a collection of pathways and biological processes rather than a single protein or receptor, it is classified as a pathway group rather than a discrete therapeutic target (Source: UniProt).

Other names

Leukemia signaling pathwaysDNA damage response in leukemiaDDR pathwaysHematologic malignancy signaling

Inhibition of oncogenic tyrosine kinases to disrupt survival signaling and inhibition of DNA repair enzymes to induce synthetic lethality or enhance chemotherapy efficacy.